Zolgensma
Pre-clinicalRecruiting 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy (SMA)
Conditions
Spinal Muscular Atrophy (SMA)
Trial Timeline
Sep 25, 2018 → Jun 30, 2038
NCT ID
NCT04174157About Zolgensma
Zolgensma is a pre-clinical stage product being developed by Novartis for Spinal Muscular Atrophy (SMA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04174157. Target conditions include Spinal Muscular Atrophy (SMA).
What happened to similar drugs?
7 of 20 similar drugs in Spinal Muscular Atrophy (SMA) were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04174157 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Spinal Muscular Atrophy (SMA)